Task force 3. Spectrum of risk factors for coronary heart disease

Journal of the American College of Cardiology

Volumn 27, Issue 5, 1996, Pages 978-990

  Pasternak, Richard C ^b   Grundy, Scott M ^b   Levy, Daniel ^b   Thompson, Paul D ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ALCOHOLISM; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SOCIAL PSYCHOLOGY; REVIEW;

CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 0030117994     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)87731-X     Document Type: Conference Paper

References (155)

1. McBride PE. The health consequences of smoking. Cardiovascular diseases. Med Clin North Am 1992;76:333-53.
2. English JP, Willus FA, Berkson J. Tobacco and coronary disease. JAMA 1940;13:1327-9,
3. Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington (D.C.): Government Printing Office, 1964.
4. Reducing the health consequences of smoking: 25 years of progress. Washington (D.C.): Government Printing Office, 1989.
5. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976;2:1525-36.
6. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1990;322(4):213-7.
7. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303-9.
8. Williams RR, Hopkins PN, Wu LL, Schumacher C, Hunt SC. Evaluating family history to prevent early coronary heart disease. Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. Dallas: American Heart Association, 1994:93-106.
9. Hopkins PN, Williams RR, Hunt SC. Magnified risks from cigarette smoking for coronary prone families in Utah. West J Med 1984;141:196-202.
10. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994;110: 121-61,
11. The health benefits of smoking cessation. A report of the Surgeon General. Washington (B.C.): U.S. Department of Health and Human Services, 1990.
12. Glantz SA, Parmley WW, Passive smoking and heart disease. Mechanisms and risk. JAMA 1995;273:1047-53.
13. Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology 1993;82:191-222.
14. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
15. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
16. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
17. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience), Prospective Cardiovascular Munster study. Am J Cardiol 1992;70(7):733-7.
18. Rossouw JE. Clinical trials of lipid-lowering drugs. Rifkind BM, editor. Drug Treatment of Hyperlipidemia. New York: Marcel Dekker, 1991:67-88.
19. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9,
21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-6.
22. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153:154-83.
23. Stamler J, Neaton J, Wentworth D. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1993;13:2-12.
24. Frohlich ED. Hypertension. Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. Dallas: American Heart Association, 1994:131-42.
25. National High Blood Pressure Education Program Working Group on primary prevention of hypertension. Arch Intern Med 1993;153(2):186-208.
26. Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 1985;7(3 Pt 1):457-68.
27. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335(8692):765-74.
28. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988;108:7-13.
29. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970;72:813-22.
30. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71:89-105.
31. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6,
32. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-8.
33. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
34. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995;273:1592-7.
35. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994;272:33-6.
36. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989;110:101-7.
37. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
38. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713-24.
39. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90: 1786-93.
40. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
41. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Current Opin Lipidol 1992;3:285-90,
42. Heller RF, Chinn S, Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. Br Med J (Clin Res Ed) 1984;288:1409-11.
43. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43.
44. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb 1992;12:1063-70.
45. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
46. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
47. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med 1993;118:956-63.
48. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992;2:457-66.
49. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-9.
50. Trip MD, Manger Cats V, Van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
51. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JWG. Ischemic heart disease and platelet aggregation: the Caerphilly Collaborative Heart Disease Study. Circulation 1991;83:38-44.
52. Brace LD, Gittler-Buffa C, Miller GJ, et al. Factor VII coagulant activity and cholesterol changes in premenopausal women consuming a long-term cholesterol-lowering diet. Arterioscler Thromb 1994;14:1284-9.
53. Poller L, MacCallum PK, Thomson JM, Kerns W. Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study. Br Heart J 1990;63:231-3.
54. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
55. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86.
56. Getz GS, Report on the workshop on diabetes and mechanisms of atherogenesis, September 17th and 18th, 1992, Bethesda, Maryland. Arterioscler Thromb 1993;13(3):459-64.
57. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Circulation 1992;15(9):1156-67.
58. Stamler J. Epidemiology, established major risk factors, and the primary prevention of coronary heart disease. Parmley WW, Chatterjee K, editors. Cardiology. Philadelphia: JB Lippincott, 1987:1-41.
59. Butler WJ, Ostrander LD, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985; 121:541-7.
60. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
61. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.
62. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992; 12:647-56.
63. Head J, Fuller JH. International variations in mortality among diabetic patients: the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1990;33:477-81.
64. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1968;128:389-401.
65. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28: 1039-57.
66. Harris MI, Hadden WC, Knowler WC, Bennett PH. International criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care 1985;8:562-7.
67. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of neuropathy in type 1 diabetes. Am J Med 1985;78:785-94.
68. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-7.
69. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987;8:253-87.
70. Haskell WL Sedentary lifestyle as a risk factor for coronary heart disease. Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. Dallas: American Heart Association, 1994:173-87.
71. Leon AS, Connett J, Jacobs DR, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. JAMA 1987;258:2388-95.
72. Morris JN, Clayton DG, Everitt MG, Semmence AM, Burgess EH. Exercise in leisure time: coronary attack and death rates. Br Heart J 1990;63:325-34.
73. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993;329: 1677-83.
74. Thompson PD, Funk EJ, Carleton RA, Stumer WQ. Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA 1982; 247(18):2535-6.
75. Worcester MC, Hare DL, Oliver RG, Reid MA, Goble AJ. Early programmes of high and low intensity exercise and quality of life after acute myocardial infarction. BMJ 1993;307:1244-7.
76. Morris JN, Everitt MG, Pollard R, Chave SP, Semmence AM. Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet 1980;2:1207-10.
77. King AC, Haskell WL, Young DR, Oka RK, Stefanick ML Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995;91:2596-604.
78. Oberman A, Fletcher GF, Lee J, et al. Efficacy of high-intensity exercise training on left ventricular ejection fraction in men with coronary artery disease (the training level comparison study). Am J Cardiol 1995;76(10): 643-7.
79. Kramsch DM, Aspen AJ, Abramowitz BM, Kreimendahl T, Hood WB, Jr. Reduction of coronary atherosclerosis by moderate conditioning exercises in monkeys on an atherogenic diet. N Engl J Med 1981;305-1482.
80. Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J Am Coll Cardiol 1993;22:468-77.
81. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80:234-44.
82. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945-50.
83. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15,
84. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995;333:677-85.
85. Williamson DF, Kahn HS, Remington PL, Anda RF. The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med 1990;150:665-72.
86. Larsson B. Regional obesity as a health hazard in men - prospective studies. Acta Med Scand Suppl 1988;723:45-51.
87. Freedman DS, Jacobsen SJ, Barboriak JJ, et al. Body fat distribution and male/female differences in lipids and lipoproteins. Circulation 1990;81: 1498-506.
88. Larsson B, Bengtsson C, Bjorntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol 1992;135:266-73.
89. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease. Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. Dallas: American Heart Association, 1994:249-54.
90. Novak ER, Williams TJ. Autopsy comparison of cardiovascular changes in castrated and normal women. Am J Obstet Gynecol 1966;80:863-72.
91. Barrett-Connor E, Bush TL Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
92. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
93. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62.
94. Friedman M, Rosenman RH. Association of specific overt behavior patterns with blood and cardiovascular findings: blood cholesterol level, blood clotting time, incidence of arcus senilis and clinical coronary artery disease. JAMA 1959;169:1286-97.
95. Rosenman RH, Brand RJ, Sholtz RI, Friedman M. Multivariate prediction of coronary heart disease during 8.5 year follow-up in the Western Collaborative Group Study. Am J Cardiol 1976;37:903-10.
96. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993;270:1819-25.
97. Williams RB. Neurobiology, cellular and molecular biology, and psychosomatic medicine. Psychosom Med 1994;56:308-15.
98. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
99. Berkman LF, Leo-Summers L, Horwitz RI. Emotional support and survival after myocardial infarction. A prospective, population-based study of the elderly. Ann Intern Med 1992; 117:1003-9.
100. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993;88:1973-98.
101. Littman AB. Review of psychosomatic aspects of cardiovascular disease. Psychother Psychosom 1993;60:148-67.
102. Barefoot JC, Patterson JC, Haney TL, Cayton TG, Hickman JR, Jr., Williams RB. Hostility in asymptomatic men with angiographically confirmed coronary artery disease. Am J Cardiol 1994;74:439-42.
103. Alfredsson L, Karasek R, Theorell T. Myocardial infarction risk and psychosocial work environment: an analysis of the male Swedish working force. Soc Sci Med 1982; 16:463-7.
104. Mittleman MA, Maclure M, Sherwood JB, et al. Triggering of acute myocardial infarction onset by episodes of anger. Circulation 1995;92: 1720-5.
105. Nunes EV, Frank KA, Kornfeld DS. Psychologic treatment for the type A behavior pattern and for coronary heart disease: a meta-analysis of the literature. Psychosom Med 1987;49;159-73.
106. Frasure-Smith N, Prince R. Long-term follow-up of the ischemic heart disease life stress monitoring program. Psychosom Med 1989;51:485-513.
107. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
108. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
109. Krauss RM, Heterogeneity of plasma low-density lipoproteins and athero-sclerosis risk. Curr Opin Lipidol 1994;5:339-49.
110. Krauss RM, Stampfer MJ, Blanche PJ, Holl LG, Ma J, Hennekens CH. Particle diameter and risk of myocardial infarction [abstract]. Circulation 1994;90 Suppl I:I-460.
111. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992;152:28-34.
112. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991; 121:1283-8.
113. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglycehdemia, and hypertension. Arch Intern Med 1989;149:1514-20.
114. Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988;259:3579-86.
115. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
116. NIH Consensus Development Panel on Triglyceride, HDL, and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505-10.
117. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991;115:209-18.
118. Kostner GM, Krempler F. Lipoprotein(a). Curr Opin Lipidol 1992;3:279-84.
119. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
120. Genest JJ, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67:1039-145.
121. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993;87:1135-41.
122. Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;13:1139-58.
123. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81.
124. Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-9.
125. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
126. Genest J, Jr., Malinow MR, Homocysteine and coronary artery disease. Clin Opin Lipidol 1992;3:295-9.
127. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
128. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
129. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
130. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
131. Stampfer MJ, Willett WC. Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. JAMA 1993;270:2726-7.
132. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
133. Jialal I, Scaccini C. Antioxidants and atherosclerosis. Curr Opin Lipid 1992;3:324-8.
134. Morris DL, Kritchevsky SB. Davis CE. Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA 1994;272:1439-41.
135. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
136. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
137. Hennekens CH, Buring JE, Peto R. Antioxidant vitamins - benefits not yet proved. N Engl J Med 1994;330:1080-1.
138. Kardinaal AFM, Aro A, Kark JD, et al. Association between B-carotene and acute myocardial infarction depends on polyunsaturated fatty acid status. The Euramic Study. Arterioscler Thromb 1995;15:726-32.
139. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha- Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
140. Manson JE, Gaziano JM, Jonas MA, Hennekens CH. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr 1993;12:426-32.
141. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-34.
142. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-73.
143. Yano K, Rhoads G, Kagan A. Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med 1977;297: 405-9.
144. Shaper A, Wannamethee G, Walker M. Alcohol and mortality in British men: explaining the u-shaped curve. Lancet 1988;1267-73.
145. Friedman GD, Klatsky AL. Is alcohol good for your health? N Engl J Med 1993;329:1882-3.
146. Criscione L, Powell JR, Burdet R, Engesser S, Schlager F, Schoepfer A. Alcohol suppresses endothelium-dependent relaxation in rat mesenteric vascular beds. Hypertension 1989;13:964-7.
147. Demrow HS, Slane PR, Folts JD, Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995;91:1182-8.
148. Pikaar NA, Wedel M, van der Beek EJ, et al. Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipids. Metabolism 1987;36:538-43.
149. Moore RD, Pearson TA. Moderate alcohol consumption and coronary artery disease. A review. Medicine (Baltimore) 1986;65:242-67.
150. Hennekens CH, Willett W, Rosner B, Cole DS, Mayrent SL. Effects of beer, wine, and liquor in coronary deaths. JAMA 1979;242:1973-4.
151. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation 1993;88:2771-9.
152. St. Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet 1979;1:1017-20.
153. Heller RF, Jacobs HS. Coronary heart disease in relation to age, sex, and the menopause. BMJ 1978;1(6111):472-4.
154. McGill HC, Jr., Stern MP. Sex and atherosclerosis. Atherosclerosis 1979; 4:157-242.
155. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981;40:1-52.